Literature DB >> 18434172

A possible in vivo generator 103Pd/103mRh--recoil considerations.

Johann van Rooyen1, Zoltan Szucs, Jan Rijn Zeevaart.   

Abstract

The use of Auger emitters as potential radiopharmaceuticals is increasingly investigated. One such radionuclide of interest is (103m)Rh. This can be produced from (103)Ru or from (103)Pd in an in vivo generator. A potential problem with this concept is the recoil of the (103m)Rh out of the carrier molecule and even out of the target cell. In order to determine whether this would happen in the (103)Pd/(103m)Rh case calculations were done to prove that this does not happen. From theoretical considerations it seems that the (103)Pd/(103m)Rh in vivo generator system would be possible.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18434172     DOI： 10.1016/j.apradiso.2008.02.088

Source DB:  PubMed          Journal:  Appl Radiat Isot        ISSN： 0969-8043            Impact factor:   1.513


  3 in total

Review 1.  In Vivo Radionuclide Generators for Diagnostics and Therapy.

Authors:  Patricia E Edem; Jesper Fonslet; Andreas Kjær; Matthias Herth; Gregory Severin
Journal:  Bioinorg Chem Appl       Date:  2016-12-12       Impact factor: 7.778

2.  Separation of 103Ru from a proton irradiated thorium matrix: A potential source of Auger therapy radionuclide 103mRh.

Authors:  Tara Mastren; Valery Radchenko; Philip D Hopkins; Jonathan W Engle; John W Weidner; Roy Copping; Mark Brugh; F Meiring Nortier; Eva R Birnbaum; Kevin D John; Michael Ernst-Heinrich Fassbender
Journal:  PLoS One       Date:  2017-12-22       Impact factor: 3.240

3.  Relevance of Palladium to Radiopharmaceutical Development Considering Enhanced Coordination Properties of TE1PA.

Authors:  Julie Pineau; Luís M P Lima; Carlos Platas-Iglesias; Jan Rijn Zeevaart; Cathryn H S Driver; Nathalie Le Bris; Raphaël Tripier
Journal:  Chemistry       Date:  2022-06-10       Impact factor: 5.020
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.